Breast Cancer Coverage from Every Angle
Editor:
William J. Gradishar, MD, FACP, FASCO
Advertisement
Advertisement

Videos

Nadia Harbeck, MD, PhD: Interpreting Recent Data on Abemaciclib Plus Endocrine Therapy in Early Breast Cancer

Javier Cortés, MD, PhD, on Chemotherapy De-escalation in HER2-Positive Early Breast Cancer: Practical Considerations From the PHERGain Trial Results

Jennifer A. Ligibel, MD, on Weight Loss and Early-Stage Breast Cancer: Impact of Telephone-Based Intervention

Anita Mamtani, MD, on When Can Axillary Dissection Be Avoided in Patients With Breast Cancer?

Judy C. Boughey, MD, on What Can Be Learned From I-SPY2 Analysis About Changes in Axillary Surgical Management

Kari M. Rosenkranz, MD, on ACOSOG Z11102: Breast Conservation Therapy and Local Recurrence

William J. Gradishar, MD, on Maturing Data From the monarchE Trial: Expanding Role for CDK4/6 Inhibitors in High-Risk Hormone-Positive Breast Cancer

Sherry X. Yang, MD, PhD, on Recurrence Score Data From the TAILORx Breast Cancer Trial

Nancy Davidson, MD, on Improving Endocrine Therapy for Patients With Breast Cancer

Ann H. Partridge, MD, MPH: New Data on Pregnancy and Breast Cancer Treatment

Joseph A. Sparano, MD, on TAILORx: Influencing the Standard of Care for Women With Node-Negative, Hormone Receptor–Positive Breast Cancer

Mafalda Oliveira, MD, PhD, on Clinical Implications of New Findings on Camizestrant in Advanced Breast Cancer

Andrea De Censi, MD: What Does the Clinical Future Look Like for Low-Dose Tamoxifen in Noninvasive Breast Cancer?

Erica L. Mayer, MD, PhD, on Clinical Considerations for New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy in Metastatic Breast Cancer

Aditya Bardia, MD, MPH, on Clinical Implications of New Findings on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

Judy C. Boughey, MD: Talking With Patients About Mastectomy vs Breast-Conserving Surgery

Mariana Chavez-MacGregor, MD, MSc: Clinical Rationale for Adding Everolimus to Adjuvant Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

Sara A. Hurvitz, MD, on Potentially Practice-Changing Findings on T-DXd vs T-DM1 in Metastatic Breast Cancer

Julia Tchou, MD, PhD, on Clinical Implications of Combining a Radiation Boost and Pembrolizumab in Triple-Negative Breast Cancer

Regina Barragán-Carrillo, MD, on Educating Physicians About Breast Cancer Screening in the Transgender Population

Marleen Kok, MD, PhD, on Preoperative Nivolumab for Triple-Negative Breast Cancer: Initial Results From the BELLINI Trial

Antonio Marra, MD, on Clinical Implications of Genomic Instability and Treatment of Advanced Breast Cancer

Erika Hamilton, MD, on T-DXd for Metastatic Breast Cancer: Clinical Considerations

Hope Rugo, MD, on Clinical Implications of New Findings on the Benefits of Sacituzumab Govitecan-hziy in Advanced Breast Cancer

Shanu Modi, MD, on Clinical Implications of New Findings on T-DXd for Metastatic Breast Cancer

Sara A. Hurvitz, MD, on the DESTINY-Breast03 Trial: T-DXd Versus T-DM1 for HER2+ Breast Cancer

Charles Coombes, MD, PhD, on Clinical Implications of Using Samuraciclib With Fulvestrant for HR–Positive HER2–Negative Breast Cancer

Peter Schmid, MD, PhD, on a Possible Practice-Changing Regimen for Patients With Early-Stage, High-Risk TNBC

Komal Jhaveri, MD, on Clinical Implications of New Data on Neratinib, Fulvestrant, and Trastuzumab for TNBC

Kevin Kalinsky, MD, on Clinical Practice Pearls: Updated Results on Endocrine Therapy and Chemotherapy for HR-Positive HER2-Negative Breast Cancer

Michael Gnant, MD: Perspective on Negative Findings With Palbociclib in HR+/HER2– Early Breast Cancer

Javier Cortés, MD, PhD, on Clinical Interpretation: First-Line Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Hans Wildiers, MD, on Clinical Implications of Adding Eftilagimod to Paclitaxel in Metastatic Breast Cancer

Yongbae Kim, MD, on Clinical Implications of Node Irradiation in Women With Node-Positive Breast Cancer

Youssef Zeidan, MD, PhD: Expert Perspective on Radiotherapy and Treatment-Related Cardiotoxicity in Breast Cancer

Hope S. Rugo, MD, on KEYNOTE-355 Findings on Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Katherine E. Reeder-Hayes, MD, MBA: Can Where Black Women Live Affect Their Breast Cancer Treatment?

Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?

Gabriel N. Hortobagyi, MD: Expert Perspective on the MONALEESA-2 Findings for HR-Positive, HER2-Negative Breast Cancer

Javier Cortés, MD, PhD: Clinical Insights on Using Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

Terry P. Mamounas, MD, MPH, on Long-Term Implications of Extended Aromatase Inhibitor Therapy for Breast Cancer

Andrew Tutt, PhD, MBChB, on Clinical Implications of Treating Metastatic Breast Cancer With Olaparib

Melinda L. Telli, MD, on Talazoparib as Monotherapy for BRCA Mutation–Positive, HER2-Negative Breast Cancer

Priya Rastogi, MD, on a Novel Approach to Predicting Benefit From Extended Letrozole Treatment for Breast Cancer

Sibylle Loibl, MD, PhD, on Adding Durvalumab to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Geoffrey J. Lindeman, MBBS, PhD, on Venetoclax Plus Fulvestrant or Fulvestrant Alone: Clinical Implications of New Findings in Breast Cancer

Nadia Harbeck, MD, PhD: Expert Perspective on De-escalating Breast Cancer Therapy With Paclitaxel, Pertuzumab, and Trastuzumab

Massimo Cristofanilli, MD, on Clinical Implications of Treatment With Palbociclib Plus Fulvestrant for Breast Cancer

Rita Nanda, MD, on Treating Triple-Negative Breast Cancer: An Expert Perspective

Dennis J. Slamon, MD, PhD, on New Approaches to Breast Cancer Treatment

Melinda L. Telli, MD, on Choosing Among Many Treatment Options for HER2-Positive Breast Cancer

William J. Gradishar, MD, on Updated NCCN Guidelines: Treatment Approaches and Research in Triple-Negative Breast Cancer

Elizabeth A. Mittendorf, MD, PhD: Clinical Pearls on Managing Local or Regional Early Breast Cancer

Sara A. Hurvitz, MD, on Evaluating Biomarkers in Triple-Negative Breast Cancer

Sibylle Loibl, MD, on Clinical Challenges Associated With Use of Palbociclib and Endocrine Therapy for HR+ HER2– Breast Cancer

Lee S. Schwartzberg, MD, on Clinical Challenges of Using Tesetaxel and Capecitabine in the Treatment of HER2– HR+ Breast Cancer

Youssef Zeidan, MD, PhD, on Boosting Radiation for HER2-Positive Breast Cancer: Why It May Not Be Necessary

Erica L. Mayer, MD, MPH, on Palbociclib Plus Endocrine Therapy in HR+/HER2– Breast Cancer

Aditya Bardia, MD, MPH, on Clinical Implications of Prescribing Sacituzumab Govitecan for Triple-Negative Breast Cancer

Monika K. Krzyzanowska, MD, MPH, on Telehealth and Quality of Life for Patients With Early Breast Cancer Receiving Chemotherapy

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Clinical Implications of Findings on Paclitaxel and Atezolizumab

Stephen R.D. Johnston, MD, PhD, on Clinical Considerations When Prescribing Abemaciclib for Early Breast Cancer

Erika P. Hamilton, MD, on Treating Breast Cancer With CDK4/6 Inhibitors: Expert Perspective

Nadia Harbeck, MD, on Trastuzumab Emtansine and Pertuzumab vs. Trastuzumab, Pertuzumab, and Taxane After Anthracyclines in Early Breast Cancer

Cynthia X. Ma, MD, PhD, on Clinical Implications of Findings on Neoadjuvant Endocrine Treatment for ER+ HER2– Breast Cancer

Seema A. Khan, MD, MPH, on Talking With Patients About Systemic Therapy vs Locoregional Treatment in Metastatic Breast Cancer

Nancy U. Lin, MD, on the HER2CLIMB Trial: Triplet Regimen for Metastatic Breast Cancer

Jennifer K. Litton, MD, on BRCA-Mutated Breast Cancer, Changing the Standard of Care, and Treatment Sequencing

Jennifer K. Litton, MD: Patient Perspective on Talazoparib vs Chemotherapy for Breast Cancer

Steven J. O’Day, MD, on Activating Innate Immunity in Triple-Negative Breast Cancer and Other Tumors

Lajos Pusztai, MD, PhD: Update on Triplet Regimen for High-Risk HER2-Negative Breast Cancer

Sara A. Hurvitz, MD, on Outcomes for Different Racial Groups Treated With Talazoparib for Breast Cancer

William J. Gradishar, MD: Can a Self-Management Patient Care Model for Breast Cancer Be Used in Other Tumor Types?

Sara M. Tolaney, MD, MPH, on Immunotherapy for Breast Cancer: Moving Into Early-Stage Disease

Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Surgery After Successful Neoadjuvant Therapy for Early Breast Cancer

Ian E. Krop, MD, PhD, on Managing Toxicities of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer

Terry P. Mamounas, MD, MPH: Is Extending Treatment With Letrozole of Benefit in Breast Cancer?

Luca Gianni, MD, on Evaluating Progress With Checkpoint Inhibitors in Breast Cancer

Jack Cuzick, PhD, on Recommending Breast Cancer Preventive Therapy

Javier Cortes, MD, PhD, on Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Milan Radovich, PhD, on Predicting Relapse in Patients With Triple-Negative Breast Cancer

Nicholas C. Turner, MD, PhD, on Using ctDNA Testing in Clinical Practice

Peter Schmid, MD, PhD, on The Future of Checkpoint Inhibitors in the Neoadjuvant Setting

Youssef Zeidan, MD, PhD, on Coping Tools for Patients Treated for Breast Cancer

Adam Brufsky, MD, PhD, on the Potential Role of Neratinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, on Early-Stage Breast Cancer: How HER2 Testing May Influence Neoadjuvant Therapy

Matteo Lambertini, MD, PhD, on Atezolizumab in Triple-Negative Breast Cancer

Joseph A. Sparano, MD, on the Prognostic Role of Clinical Risk Stratification in ER-Positive, HER2-Negative Breast Cancer

Sara A. Hurvitz, MD, on Ribociclib Plus Endocrine Therapy for Premenopausal Women With Advanced Breast Cancer

Hope S. Rugo, MD, on Using Margetuximab in the Community Setting for HER2-Positive Metastatic Breast Cancer

Peter Schmid, MD, PhD: Update on IMpassion130: Use of Doublet to Treat Triple-Negative Breast Cancer

William J. Gradishar, MD, on Atezolizumab and Nab-paclitaxel in Triple-Negative Breast Cancer

Patricia A. Ganz, MD, on Comparing Radiation Therapies for Breast Cancer: Patient-Reported Outcomes

William J. Gradishar, MD, on HER2-Negative Breast Cancer: The Treatment Pipeline

G. Travis Clifton, MD, on Breast Cancer: Using a Cancer Vaccine With and Without Trastuzumab to Prevent Recurrences

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Expert Perspective

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Shom Goel, MD, PhD, on Use of CDK4/6 Inhibitors in Breast Cancer to Enhance Antitumor Immunity

Hope S. Rugo, MD, on Immunotherapy Combinations for Breast Cancer

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Roisin M. Connolly, MD, on Yearly Review of Breast Cancer Treatment Advances

Kathy S. Albain, MD, on Racial Disparities in Breast Cancer Outcomes From TAILORx Trial

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Treatment Debate Over Breast Cancer With Positive Lymph Nodes

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Marleen Kok, MD, PhD, on Luminal Breast Cancer: Immunotherapy Strategies

Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on Immunotherapy for TNBC: IMpassion130 Results

Matthew J. Ellis, MB, BChir, PhD, on Endocrine Therapy Alone or in Combination for Postmenopausal Women With Breast Cancer

Anthony D. Elias, MD, on Balancing Treatment and Quality of Life

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Use of Sacituzumab Govitecan in Metastatic Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Chemoendocrine Treatment in Breast Cancer: the TAILORx Trial

Helena Margaret Earl, MBBS, PhD, on Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: PARP Inhibitors in the Current Treatment Landscape

William J. Gradishar, MD, on Balancing Treatment and Quality of Life

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Guideline Updates

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Treatment Options in Breast Cancer

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Meredith M. Regan, ScD, on Early Breast Cancer: Update on the TEXT and SOFT Trials

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

Ruth M. O’Regan, MD, and Douglas Yee, MD: Results From the I-SPY2 Trial

Ruth M. O’Regan, MD, and Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Hope S. Rugo, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial

Cristina Saura, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Sibylle Loibl, MD, PhD, on Managing Neutropenia Associated with CDK Inhibitors

Declan Walsh, MD, on Opioid-Induced Nausea and Vomiting: Tips for Daily Practice

Cristina Saura, MD, on Breast Cancer: Results from the LORELEI Trial

William J. Gradishar, MD, on Triple-Negative Breast Cancer: Expert Perspective on the KEYNOTE-086 Trial Results

Benjamin O. Anderson, MD, on NCCN’s Resource-Stratified Framework: Expert Perspective

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

William J. Gradishar, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

George W. Sledge, MD, on HR+/HER2– Breast Cancer: Results From the MONARCH 2 Trial

William J. Gradishar, MD, and Rita Nanda, MD, on High-Risk Breast Cancer: Results From the I-SPY 2 Trial

William J. Gradishar, MD, on Endocrine Therapy for Breast Cancer

William J. Gradishar, MD, and Kilian E. Salerno, MD, on Evolving Radiation Therapy Recommendations

Lee S. Schwartzberg, MD, on Biomarkers and Gene Assays

George Somlo, MD, on Breast Cancer and TILs: Treatment Challenges

Harold J. Burstein, MD, PhD, and William J. Gradishar, MD, on ER+ Breast Cancer: Coming Changes in Treatment

G. Thomas Budd, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

William J Gradishar, MD, on NCCN Guidelines: Process, Evolution, and Clinical Practice

The JNCCN Spotlight

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.